Role of suppressors of cytokine signaling 3 in bone inflammatory responses

Frontiers in Immunology

Volumn 4, Issue DEC, 2013, Pages

  Gao, Anqi ^a   Van Dyke, Thomas E ^a  

^a FORSYTH INSTITUTE   (United States)

Author keywords

Bone; Inflammation; SOCS3

Indexed keywords

COLLAGENASE 3; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH HORMONE; INTERLEUKIN 1; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; CYCLOHEXIMIDE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKEMIA INHIBITORY FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; BONE DESTRUCTION; BONE DISEASE; BONE REMODELING; CARTILAGE CELL; GENE EXPRESSION; HUMAN; INFLAMMATION; MUSCULOSKELETAL SYSTEM INFLAMMATION; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOMYELITIS; PERIODONTAL DISEASE; PORPHYROMONAS GINGIVALIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; ARTHRITIS; BONE DYSPLASIA; OSTEOLYSIS; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84987788690     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity (2008) 28:477-87. doi: 10.1016/j.immuni.2008.03.002.
2. Taleb S, Romain M, Ramkhelawon B, Uyttenhove C, Pasterkamp G, Herbin O, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med (2009) 206:2067-77. doi:10.1084/jem.20090545.
3. Morales O, Faulds MH, Lindgren UJ, Haldosen LA. 1Alpha,25-dihydroxyvitamin D3 inhibits GH-induced expression of SOCS-3 and CIS and prolongs growth hormone signaling via the Janus kinase (JAK2)/signal transducers and activators of transcription (STAT5) system in osteoblast-like cells. J Biol Chem (2002) 277:34879-84. doi:10.1074/jbc.M204819200.
4. Yan C, Cao J, Wu M, Zhang W, Jiang T, Yoshimura A, et al. Suppressor of cytokine signaling 3 inhibits LPS-induced IL-6 expression in osteoblasts by suppressing CCAAT/enhancer-binding protein {beta} activity. J Biol Chem (2010) 285:37227-39. doi:10.1074/jbc.M110.132084.
5. Gao A, Kantarci A, Herrera B, Gao H, Van Dyke TE. A critical role for suppressors of cytokine signaling 3 in regulating LPS-induced transcriptional activation of matrix metalloproteinase-13 in osteoblasts. Peer J (2013) 1:e51. doi:10.7717/peerj.51.
6. Bergamin E, Wu J, Hubbard SR. Structural basis for phosphotyrosine recognition by suppressor of cytokine signaling-3. Structure (2006) 14:1285-92. doi:10.1016/j.str.2006.06.011.
7. Boyle K, Egan P, Rakar S, Willson TA, Wicks IP, Metcalf D, et al. The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood (2007) 110:1466-74. doi:10.1182/blood-2007-03-079178.
8. Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity (2012) 36:239-50. doi:10.1016/j.immuni.2011.12.015.
9. Haan S, Ferguson P, Sommer U, Hiremath M, McVicar DW, Heinrich PC, et al. Tyrosine phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation. J Biol Chem (2003) 278:31972-9. doi:10.1074/jbc.M303170200.
10. Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells (1999) 4:339-51. doi:10.1046/j.1365-2443.1999.00263.x.
11. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, et al. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J (1999) 18:1309-20. doi:10.1093/emboj/18.5.1309.
12. Rossa C Jr, Liu M, Bronson P, Kirkwood KL. Transcriptional activation of MMP-13 by periodontal pathogenic LPS requires p38 MAP kinase. J Endotoxin Res (2007) 13:85-93. doi:10.1177/0968051907079118.
13. Fox SW, Haque SJ, Lovibond AC, Chambers TJ. The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. J Immunol (2003) 170:3679-87.
14. Hayashi T, Kaneda T, Toyama Y, Kumegawa M, Hakeda Y. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. J Biol Chem (2002) 277:27880-6. doi:10.1074/jbc.M203836200.
15. Ruan M, Pederson L, Bradley EW, Bamberger AM, Oursler MJ. Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis. Endocrinology (2010) 151:1713-22. doi:10.1210/en.2009-0813.
16. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature (1997) 387:917-21. doi:10.1038/43206.
17. Wong PK, Egan PJ, Croker BA, O'Donnell K, Sims NA, Drake S, et al. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest (2006) 116:1571-81. doi:10.1172/JCI25660.
18. Ben-Zvi T, Yayon A, Gertler A, Monsonego-Ornan E. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fibroblast growth factor receptor signaling. J Cell Sci (2006) 119:380-7. doi:10.1242/jcs.02740.
19. Smeets RL, Veenbergen S, Arntz OJ, Bennink MB, Joosten LA, van den Berg WB, et al. A novel role for suppressor of cytokine signaling 3 in cartilage destruction via induction of chondrocyte desensitization toward insulin-like growth factor. Arthritis Rheum (2006) 54:1518-28. doi:10.1002/art.21752.
20. Krejci P, Prochazkova J, Bryja V, Jelinkova P, Pejchalova K, Kozubik A, et al. Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal (2009) 21:151-60. doi:10.1016/j.cellsig.2008.10.006.
21. de Andres MC, Imagawa K, Hashimoto K, Gonzalez A, Goldring MB, Roach HI, et al. Suppressors of cytokine signalling (SOCS) are reduced in osteoarthritis. Biochem Biophys Res Commun (2011) 407:54-9. doi:10.1016/j.bbrc.2011.02.101.
22. van de Loo FA, Veenbergen S, van den Brand B, Bennink MB, Blaney-Davidson E, Arntz OJ, et al. Enhanced suppressor of cytokine signaling 3 in arthritic cartilage dysregulates human chondrocyte function. Arthritis Rheum (2012) 64:3313-23. doi:10.1002/art.34529.
23. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov (2013) 12:611-29. doi:10.1038/nrd4088.
24. Sun X. Expressions of SOCS in chondrocytes of patients with osteoarthritis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2013) 29:186-9.
25. O'Brien CA, Gubrij I, Lin SC, Saylors RL, Manolagas SC. STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp130-utilizing cytokines or interleukin-1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J Biol Chem (1999) 274:19301-8.
26. Kwak HB, Kim HS, Lee MS, Kim KJ, Choi EY, Choi MK, et al. Pyridone 6, a pan-Janus-activated kinase inhibitor, suppresses osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression. Biol Pharm Bull (2009) 32:45-50.
27. Mori T, Miyamoto T, Yoshida H, Asakawa M, Kawasumi M, Kobayashi T, et al. IL-1beta and TNFalpha-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol (2011) 23:701-12. doi:10.1093/intimm/dxr077.
28. Krause A, Scaletta N, Ji JD, Ivashkiv LB. Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol (2002) 169:6610-6.
29. Han SK, Jeon SJ, Miyazawa K, Yi SY, Yoo YS. Enhancement of anti-inflammatory tendency by SB203580, p38alpha specific inhibitor, in human fibroblast-like synoviocyte cell line, MH7A. Rheumatol Int (2006) 26:972-8. doi:10.1007/s00296-006-0109-4.
30. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest (2001) 108:1781-8. doi:10.1172/JCI200113568.
31. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol (2003) 30:2193-200.
32. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S. Comparison of anti-arthritic properties of leflunomide with methotrexate and FK506: effect on T cell activation-induced inflammatory cytokine production in vitro and rat adjuvant-induced arthritis. Inflam Res (2004) 53:544-50. doi:10.1007/s00011-004-1294-9.
33. Hirotani H, Tuohy NA, Woo JT, Stern PH, Clipstone NA. The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem (2004) 279:13984-92. doi:10.1074/jbc.M213067200.
34. Miyazaki M, Fujikawa Y, Takita C, Tsumura H. Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis. Clin Rheumatol (2007) 26:231-9. doi:10.1007/s10067-006-0287-1.
35. Choe JY, Park KY, Park SH, Lee SI, Kim SK. Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. Arthritis Res Ther (2013) 15:R26.
36. Moffatt CE, Lamont RJ. Porphyromonas gingivalis induction of microRNA-203 expression controls suppressor of cytokine signaling 3 in gingival epithelial cells. Infect Immun (2011) 79:2632-7. doi:10.1128/IAI.00082-11.
37. Fukushima A, Kajiya H, Izumi T, Shigeyama C, Okabe K, Anan H. Pro-inflammatory cytokines induce suppressor of cytokine signaling-3 in human periodontal ligament cells. J Endod (2010) 36:1004-8. doi:10.1016/j.joen.2010.02.027.
38. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med (2001) 193:471-81. doi:10.1084/jem.193.4.471.
39. Ogura H, Murakami M, Okuyama Y, Tsuruoka M, Kitabayashi C, Kanamoto M, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity (2008) 29:628. doi:10.1016/j.immuni.2008.07.018.
40. Murakami M, Okuyama Y, Ogura H, Asano S, Arima Y, Tsuruoka M, et al. Local microbleeding facilitates IL-6-and IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells. J Exp Med (2011) 208:103. doi:10.1084/jem.20100900.
41. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A (2006) 103(21):8137-42. doi:10.1073/pnas.0600666103.
42. Qin H, Wang L, Feng T, Elson CO, Niyongere SA, Lee SJ, et al. TGF-beta promotes Th17 cell development through inhibition of SOCS3. J Immunol (2009) 183(1):97-105. doi:10.4049/jimmunol.0801986.
43. Davignon JL, Hayder M, Baron M, Boyer JF, Constantin A, Apparailly F, et al. Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology (2013) 52:4. doi:10.1093/rheumatology/kes304.
44. Qin H, Holdbrooks AT, Liu Y, Reynolds SL, Yanagisawa LL, Benveniste EN. SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J Immunol (2012) 189(7):3439-48. doi:10.4049/jimmunol.1201168.
45. Heeg K, Dalpke A. TLR-induced negative regulatory circuits: role of suppressor of cytokine signaling (SOCS) proteins in innate immunity. Vaccine (2003) 21(Suppl 2):S61-7. doi:10.1016/S0264-410X(03)00202-0.
46. Ohishi M, Matsumura Y, Aki D, Mashima R, Taniguchi K, Kobayashi T, et al. Suppressors of cytokine signaling-1 and-3 regulate osteoclastogenesis in the presence of inflammatory cytokines. J Immunol (2005) 174:3024-31.